4.7 Letter

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab

Journal

JAMA NETWORK OPEN
Volume 6, Issue 7, Pages -

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamanetworkopen.2023.23398

Keywords

-

Ask authors/readers for more resources

This study examines the recent list and net prices of Humira with rebates, comparing them with the announced prices of interchangeable biosimilar formulations of Humira.
This cross-sectional study compares recent list and net prices for Humira after rebates with announced prices of interchangeable biosimilar Humira formulations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available